CORRECTION: NeoGenomics Ticker Is NEO
$NE
$NEO
Oil & Gas Production
Energy
Precision Instruments
Health Care
CORRECTION: NeoGenomics Ticker Is NEO
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 10/15/2024 | Buy → Hold | The Benchmark Company | ||
| 5/1/2024 | $26.00 | Buy | Craig Hallum | |
| 12/29/2023 | $25.00 → $21.00 | Buy | BTIG Research | |
| 12/1/2023 | $52.00 | Neutral | Susquehanna | |
| 11/28/2023 | $62.00 | Overweight | CapitalOne | |
| 8/21/2023 | $18.00 | Equal-Weight → Overweight | Stephens | |
| 7/5/2023 | $64.00 | Buy | Citigroup | |
| 5/16/2023 | Outperform → Mkt Perform | Raymond James |
-Reuters
Although U.S. stocks closed higher on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform. Noble Corporation The Trade: Noble Corporation plc (NYSE:NE) 10% owner APMH Invest A/S acquired a total of 638,018 shares at
Susquehanna analyst Charles Minervino maintains Noble Corp (NYSE:NE) with a Neutral and lowers the price target from $49 to $47.
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - Noble Corp plc (0001895262) (Issuer)
4 - Noble Corp plc (0001895262) (Issuer)
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)
SC 13D/A - Noble Corp plc (0001895262) (Subject)
SC 13D/A - Noble Corp plc (0001895262) (Subject)
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will present four abstracts at the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo in Vancouver, Canada, November 19-23 (booth #830). The research demonstrates how ctDNA and next-generation sequencing (NGS) can drive more personalized and accurate treatment options for cancer patients. "Our presence at AMP 2024 underscores NeoGenomics' dedication to advancing cancer care through ongoing research in precision medicine," said Warren Stone, CCO of NeoGenomics. "By continuing to improve our methods and technologies, we aim to enhance outcomes and set new standards for oncology testing." NeoGeno
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced the appointment of Felicia Williams to its Board of Directors. "We are fortunate to welcome Felicia Williams to our board of directors, bringing her experience across the spectrum of finance, accounting, audit, and enterprise risk management to NeoGenomics," said Lynn Tetrault, Chairwoman of the Board of NeoGenomics. "We look forward to working together to support the company and improve patient care." The Board has elected Felicia Williams to join the Board as an independent director effective November 1, 2024. Felicia, former interim CFO of Macy's Inc. and Fellow for CEO Action for Racial Equa
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will attend the Piper Sandler 36th Annual Healthcare Conference. Members of the management team will participate in an in-person fireside chat on Thursday, Dec. 5, 2024, at 9:30 a.m. ET in New York City. The presentation will be webcast live and accessible online via this link. A replay will be available on the Investor Relations section of the Company's website at ir.neogenomics.com. About NeoGenomics, Inc. NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus for physicians to help them diagnose and treat cancer
Closed Diamond acquisition on September 4thIncreased capital return program with additional share repurchase authorization of $400 millionRepurchased 6.9 million of shares in Q3 2024, $0.50 per share dividend declared for Q4 2024, bringing total FY 2024 cash returns to shareholders to over $525 million, including Q4 dividendQ3 Net Income of $61 million, Diluted Earnings Per Share of $0.40, Adjusted EBITDA of $291 million, net cash provided by operating activities of $284 million, and Free Cash Flow of $165 millionQ4 2024 Guidance provided as follows: Total Revenue $850 to $890 million, Adjusted EBITDA $275 to $305 million, Capital Additions (net of reimbursements) $105 to $135 millionSUGAR L
Adjusted EBITDA Improves 305%; Fifth Consecutive Quarter of Positive Adjusted EBITDA; Increasing FY Guidance to $37-$40 Million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, 2024. Third Quarter 2024 Highlights As Compared To Third Quarter 2023 Consolidated revenue increased 10% to $168 million Clinical Services revenue increased 14% to $146 million Advanced Diagnostics revenue decreased 10% to $22 million Net loss decreased 4% to $18 million Adjusted EBITDA increased 305% to positive $13 million "We delivered a strong third quarter, again gro
SUGAR LAND, Texas, Oct. 18, 2024 /PRNewswire/ -- Noble Corporation plc ("Noble" or the "Company") (CSE:NOBLE, NYSE:NE) today announces plans to report financial results for the third quarter 2024 on Tuesday November 5, 2024 after the U.S. market close. The Company's earnings press release and accompanying earnings presentation will be available on the Noble website at www.noblecorp.com. Noble will host a conference call related to its third quarter 2024 results on Wednesday, November 6, 2024 at 8:00 a.m. U.S. Central Time. Interested parties may dial +1 (800) 715-9871 and refer to conference ID 31391 approximately 15 minutes prior to the scheduled start time. Alternatively, a live webcast
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced the appointment of Felicia Williams to its Board of Directors. "We are fortunate to welcome Felicia Williams to our board of directors, bringing her experience across the spectrum of finance, accounting, audit, and enterprise risk management to NeoGenomics," said Lynn Tetrault, Chairwoman of the Board of NeoGenomics. "We look forward to working together to support the company and improve patient care." The Board has elected Felicia Williams to join the Board as an independent director effective November 1, 2024. Felicia, former interim CFO of Macy's Inc. and Fellow for CEO Action for Racial Equa
PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (the ‘Company' or ‘Biocartis'), an innovative molecular diagnostics company, is pleased to announce the appointment of Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as Vice President Global Marketing. Gina Wallar, PhD as Chief Business Officer: Gina Wallar was appointed as Biocartis' Chief Business Officer on 15 April 2024 and will be responsible for Biocartis' business development and partnering initiatives, as well as US commercialization. Dr. Wallar has more than 20 year
FT. MYERS, FL / ACCESSWIRE / June 29, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced the appointment of Elizabeth Floegel, Neil Gunn, and Tony Zook to its Board of Directors.The Board has elected three new independent board members to join the board effective June 29, 2023. Elizabeth Floegel, Chief Information & Digital Officer of Numotion, a complex rehabilitation technology provider, will be a member of the Audit & Finance and Compliance Committees. Neil Gunn, former Chief Executive Officer of IDbyDNA, a developer of metagenomic technology for infectious disease testing and pathogen surveillance which was
4 - Noble Corp plc (0001895262) (Issuer)
4 - Noble Corp plc (0001895262) (Issuer)
4 - Noble Corp plc (0001895262) (Issuer)
8-K/A - Noble Corp plc (0001895262) (Filer)
144 - Noble Corp plc (0001895262) (Subject)
144 - Noble Corp plc (0001895262) (Subject)
The Benchmark Company downgraded Noble Corporation from Buy to Hold
Craig Hallum resumed coverage of NeoGenomics with a rating of Buy and set a new price target of $26.00
BTIG Research reiterated coverage of NeoGenomics with a rating of Buy and set a new price target of $21.00 from $25.00 previously
